Background: T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LL) and are often thought to represent a spectrum of a single disease. The malignant cells in T-ALL and T-LL are morphologically indistinguishable, and they share the expression of common cell surface antigens and cytogenetic characteristics. However, despite these similarities, differences in the clinical behavior of T-ALL and T-LL are observed.

Procedure: We analyzed the gene expression profiles of T-ALL and T-LL samples obtained from Children's Oncology Group (COG) tumor banks using DNA arrays. Immunohistochemistry was also performed to validate the expression of selected targets.

Results: Unsupervised hierarchical clustering of all samples showed complete segregation of T-ALL and T-LL into distinct clusters. Next, we identified the top 201 genes that best differentiated T-ALL from T-LL using significance analysis of microarrays (SAM), a supervised statistical approach. Genes representing several functional groups were differentially expressed in T-LL and T-ALL. Prediction analysis of microarrays (PAM) identified a subset of genes, which accurately classified all 19 T-ALL and T-LL samples with an overall misclassification error rate of 0. Immunohistochemical validation of protein expression of selected genes identified by microarray analysis confirmed overexpression of MLL-1 in T-LL tumor cells compared to T-ALL and CD47 in T-ALL tumors cells when compared to T-LL.

Conclusions: Despite significant similarities between the malignant T-cell precursors, clear differences in the gene expression profiles were observed between T-ALL and T-LL implying underlying differences in the biology of the two entities.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.20550DOI Listing

Publication Analysis

Top Keywords

t-all t-ll
28
gene expression
12
t-all
11
t-ll
10
t-cell acute
8
acute lymphoblastic
8
lymphoblastic leukemia
8
t-cell lymphoblastic
8
lymphoblastic lymphoma
8
despite similarities
8

Similar Publications

Article Synopsis
  • Defining prognostic factors for T-lymphoblastic lymphoma (T-LL) is complex, as shown in the AALL1231 trial that included children and young adults with T acute lymphoblastic leukemia or T-LL, comparing standard therapy with the addition of bortezomib.
  • In the trial, 41% of patients provided bone marrow samples to measure minimal residual disease (MRD) after treatment, revealing that those with MRD levels below 0.1% had a significantly better event-free survival rate (89%) compared to those with MRD at or above 0.1% (64%).
  • Cox regression analysis indicated that having MRD levels at or above 0.1%
View Article and Find Full Text PDF

While outcomes for children with T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LL) have improved significantly with contemporary therapy, outcomes for patients with relapsed or refractory (r/r) disease remain dismal. Improved risk stratification and the incorporation of novel therapeutics have the potential to improve outcomes further in T-ALL/T-LL by limiting relapse risk and improving salvage rates for those with r/r disease. In this review we will discuss the challenges and new opportunities for improved risk stratification in T-ALL and T-LL.

View Article and Find Full Text PDF

T- lymphoblastic leukemia/lymphoma (T-LL) is an aggressive malignancy of immature T-cells with poor overall survival (OS) and in need of new therapies. LIM-domain only 2 (LMO2) is a critical regulator of hematopoietic cell development that can be overexpressed in T-LL due to chromosomal abnormalities. Deregulated LMO2 expression contributes to T-LL development by inducing block of T-cell differentiation and continuous thymocyte self-renewal.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to enhance the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL) by testing the proteasome inhibitor bortezomib and reducing the use of prophylactic cranial radiation (CRT) in newly diagnosed patients.
  • In a clinical trial involving over 800 patients, a modified chemotherapy regimen was used, comparing outcomes between patients who received bortezomib and those who did not, with the goal of assessing event-free survival (EFS) and overall survival (OS).
  • Results indicated that bortezomib significantly improved EFS and OS for T-LL patients, while allowing a dramatic reduction in CRT usage
View Article and Find Full Text PDF

High-dose methotrexate (HDMTX) is an important component of treatment in pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). Optimal rescue therapy is essential for the safe administration of HDMTX. A cost-effective strategy that does not compromise safety is necessary for low- and middle-income countries.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!